Abstract: A method for enhancing extracellular vesicle production is described. A peptide that induces polymer formation is incubated with a cell culture which results in enhanced EV production. The peptide penetrates the cells and subsequently polymerizes upon exposure to enzymes (e.g. phosphatase) within the cell. The cells that contain the newly formed polymers have an increased production of EVs. These EVs can be harvested using centrifugation techniques.

Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.

Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.

Abstract: A coating agent for preventing the adsorption of extracellular vesicles represented by exosomes to a tool has been developed. Adsorption of extracellular vesicles to a tool can be prevented by using a coating agent which contains a hydrophilic polymer having a weight average molecular weight of 10,000 or more and 1,000,000 or less, wherein a coated layer formed by the coating agent has a contact angle of 0 degree or more and 30 degrees or less.

Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.

Abstract: A coating agent for preventing the adsorption of extracellular vesicles represented by exosomes to a tool has been developed. Adsorption of extracellular vesicles to a tool can be prevented by using a coating agent which contains a hydrophilic polymer having a weight average molecular weight of 10,000 or more and 1,000,000 or less, wherein a coated layer formed by the coating agent has a contact angle of 0 degree or more and 30 degrees or less.

Abstract: The present disclosure provides examples of methods and kits for easily detecting, classifying and/or purifying extracellular vesicles. The method can include subjecting, to a density gradient centrifugation, a sample solution in which the extracellular vesicles and nanoparticles coated with ligand that specifically binds to molecule present on the surface of the extracellular vesicles are mixed.

Abstract: A method for enhancing extracellular vesicle production is described. A peptide that induces polymer formation is incubated with a cell culture which results in enhanced EV production. The peptide penetrates the cells and subsequently polymerizes upon exposure to enzymes (e.g. phosphatase) within the cell. The cells that contain the newly formed polymers have an increased production of EVs. These EVs can be harvested using centrifugation techniques.

Abstract: [Problem to be Solved] An object of the present invention is to provide a novel peptide that has the high ability to bind to EpCAM, which can be easily prepared by a chemical synthesis method or a genetic engineering method. [Solution] The present inventors have improved a method for screening a phage library and thereby successfully screened for a peptide that has the higher ability to bind to EpCAM compared with publicly known peptides. The present inventors have also used an already disclosed peptide having the ability to bind to EpCAM as a lead compound to prepare diverse populations of derivatives thereof, from among which a peptide strongly binding to EpCAM has been selected. The obtained peptides exhibit at least 10 times higher ability to bind to EpCAM compared with publicly known peptides and as such, are effective for the detection or diagnosis of cancer cells.

Abstract: A method for enhancing extracellular vesicle production is described. A peptide that induces polymer formation is incubated with a cell culture which results in enhanced EV production. The peptide penetrates the cells and subsequently polymerizes upon exposure to enzymes (e.g. phosphatase) within the cell. The cells that contain the newly formed polymers have an increased production of EVs. These EVs can be harvested using centrifugation techniques.

Abstract: Provide is a stable metallic nanostructure that causes no aggregation when surface-modified with biomolecule-reactive functional molecules. 30 to 90% of the surface of the metallic nanostructure is covered with at least one or more types of colloid-stabilizing functional molecules. Furthermore, the metallic nanostructure is covered with one or more types of biologically functional molecules.

Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.

Abstract: [Problem to be Solved] An object of the present invention is to provide a novel peptide that has the high ability to bind to EpCAM, which can be easily prepared by a chemical synthesis method or a genetic engineering method. [Solution] The present inventors have improved a method for screening a phage library and thereby successfully screened for a peptide that has the higher ability to bind to EpCAM compared with publicly known peptides. The present inventors have also used an already disclosed peptide having the ability to bind to EpCAM as a lead compound to prepare diverse populations of derivatives thereof, from among which a peptide strongly binding to EpCAM has been selected. The obtained peptides exhibit at least 10 times higher ability to bind to EpCAM compared with publicly known peptides and as such, are effective for the detection or diagnosis of cancer cells.

Abstract: It is intended to provide a stable metallic nanostructure that causes no aggregation when surface-modified with biomolecule-reactive functional molecules. 30 to 90% of the surface of a metallic nanostructure is covered with at least one or more types of colloid-stabilizing functional molecules. The remaining portions on the surface of the metallic nanostructure are further covered with one or more types of biologically functional molecules.

Abstract: It is to provide an inorganic thin film of titanium dioxide or the like which is controlled at the nanoscale and a three-dimensional structure of a functional material such as semiconductor nanoparticles.

Abstract: The present invention makes it possible to efficiently recognize carbon nanotubes, carbon nanohorns or modifiers thereof and to support functional compounds by fusing the ability of ferritin molecules capable of forming nanoparticles of inorganic metal atoms or inorganic metal compounds. In addition, because ferritin molecules are capable of forming two-dimensional crystals at the interface, the present invention makes it possible to align carbon nanotubes, carbon nanohorns with the use of the molecular arrangement ability of ferritin fused with nanographite structure recognition peptides.

Abstract: It is to provide an inorganic thin film of titanium dioxide or the like which is controlled at the nanoscale and a three-dimensional structure of a functional material such as semiconductor nanoparticles.

Abstract: The present invention makes it possible to efficiently recognize carbon nanotubes, carbon nanohorns or modifiers thereof and to support functional compounds by fusing the ability of ferritin molecules capable of forming nanoparticles of inorganic metal atoms or inorganic metal compounds. In addition, because ferritin molecules are capable of forming two-dimensional crystals at the interface, the present invention makes it possible to align carbon nanotubes, carbon nanohorns with the use of the molecular arrangement ability of ferritin fused with nanographite structure recognition peptides.

Abstract: The present invention provides a carbon nanohorn complex that is excellent in characteristics of adsorption or inclusion of drugs and release, in particular, a sustained release of drugs as a novel drug carrier in drug delivery systems, as well as a process for producing the complex. The complex of drug and carbon nanohorns comprises a steroidal or metal-containing drug being adsorbed onto the oxidized carbon nanohorns, or included in pores opened thereof.

Abstract: The present invention provides a peptide sequence, a phage, an artificial protein or a chimeric molecule having a binding ability to titanium, silver, silicon, necessary to confer higher capacity of titanium, silver, silicon material with the use of soft matters, or to provide a complex of a peptide, a phage, an artificial protein or a chimeric molecule, and titanium, having the peptide sequence and functional peptide sequence. By bringing into contact a population of phage wherein said phage of said population collectively express a library of different peptide sequence, recovering titanium bound to phage particles via peptide sequence by centrifugation, proliferating the obtained phage particles in bacteria, and repeating panning operation and concentrating titanium binding phage clones. Among the phage clones, peptide RKLPDAPGMHTW (SEQ ID NO: 3) and the like is identified.